Paper950490
Production of epidermal acantholysis in normal human skin in vitro by the IgG fraction from pemphigus serum.
Schiltz JR and 1 other. J Invest Dermatol, 1976. Cited by 231 papers, by iCite.
Cite this record
ConductScience Library. Production of epidermal acantholysis in normal human skin in vitro by the IgG fraction from pemphigus serum. Papers, record 950490. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/950490
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Production of epidermal acantholysis in normal human skin in vitro by the IgG fraction from pemphigus serum.
- PubMed
Topics10
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Acantholysis | Major topic |
| Immunoglobulin G | Major topic |
| Pemphigus | Major topic |
| Skin | Major topic |
| Skin Diseases | Major topic |
| Acanthocytes | |
| Autoantibodies | |
| Autoradiography | |
| Culture Techniques | |
| Humans |
Source PubMed
Cited by46
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 231 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 37503332 | Blocking soluble Fas Ligand ameliorates pemphigus: PC111 efficacy in ex-vivo human pemphigus models. | Front Immunol | 2023 | https://conductscience.org/library/papers/37503332 | PubMed |
| 35720332 | Mechanisms Causing Acantholysis in Pemphigus-Lessons from Human Skin. | Front Immunol | 2022 | https://conductscience.org/library/papers/35720332 | PubMed |
| 35330080 | Marked to Die-Cell Death Mechanisms for Keratinocyte Acantholysis in Pemphigus Diseases. | Life (Basel) | 2022 | https://conductscience.org/library/papers/35330080 | PubMed |
| 31552014 | Serological Diagnosis of Autoimmune Bullous Skin Diseases. | Front Immunol | 2019 | https://conductscience.org/library/papers/31552014 | PubMed |
| 30155465 | The Evolving Story of Autoantibodies in Pemphigus Vulgaris: Development of the "Super Compensation Hypothesis". | Front Med (Lausanne) | 2018 | https://conductscience.org/library/papers/30155465 | PubMed |
| 25795143 | Desmosomes in acquired disease. | Cell Tissue Res | 2015 | https://conductscience.org/library/papers/25795143 | PubMed |
| 20978359 | Homologous regions of autoantibody heavy chain complementarity-determining region 3 (H-CDR3) in patients with pemphigus cause pathogenicity. | J Clin Invest | 2010 | https://conductscience.org/library/papers/20978359 | PubMed |
| 20964642 | Efficacy of intravenous immunoglobulin (IVIG) affinity-purified anti-desmoglein anti-idiotypic antibodies in the treatment of an experimental model of pemphigus vulgaris. | Clin Exp Immunol | 2010 | https://conductscience.org/library/papers/20964642 | PubMed |
| 20671975 | Targeted immunotherapy with rituximab leads to a transient alteration of the IgG autoantibody profile in pemphigus vulgaris. | Dermatol Res Pract | 2010 | https://conductscience.org/library/papers/20671975 | PubMed |
| 20585596 | Experimental human cell and tissue models of pemphigus. | Dermatol Res Pract | 2010 | https://conductscience.org/library/papers/20585596 | PubMed |
| 20467217 | Autoimmune and infectious skin diseases that target desmogleins. | Proc Jpn Acad Ser B Phys Biol Sci | 2010 | https://conductscience.org/library/papers/20467217 | PubMed |
| 20178468 | Update on the cloning of monoclonal anti-desmoglein antibodies from human pemphigus patients: implications for targeted therapy. | Vet Dermatol | 2009 | https://conductscience.org/library/papers/20178468 | PubMed |
| 18386043 | The desmosome and pemphigus. | Histochem Cell Biol | 2008 | https://conductscience.org/library/papers/18386043 | PubMed |
| 17130286 | Inhibition of Rho A activity causes pemphigus skin blistering. | J Cell Biol | 2006 | https://conductscience.org/library/papers/17130286 | PubMed |
| 16297153 | Protective effect of intravenous immunoglobulin (IVIG) in an experimental model of pemphigus vulgaris. | Clin Exp Immunol | 2005 | https://conductscience.org/library/papers/16297153 | PubMed |
| 11120754 | Antibodies against keratinocyte antigens other than desmogleins 1 and 3 can induce pemphigus vulgaris-like lesions. | J Clin Invest | 2000 | https://conductscience.org/library/papers/11120754 | PubMed |
| 10712434 | Use of autoantigen-knockout mice in developing an active autoimmune disease model for pemphigus. | J Clin Invest | 2000 | https://conductscience.org/library/papers/10712434 | PubMed |
| 9710446 | Antibodies against desmoglein 3 (pemphigus vulgaris antigen) are present in sera from patients with paraneoplastic pemphigus and cause acantholysis in vivo in neonatal mice. | J Clin Invest | 1998 | https://conductscience.org/library/papers/9710446 | PubMed |
| 8931866 | Proteinase inhibitors and pemphigus vulgaris. An in vitro and in vivo study. | Arch Dermatol Res | 1996 | https://conductscience.org/library/papers/8931866 | PubMed |
| 8486729 | Nomenclature of the desmosomal cadherins. | J Cell Biol | 1993 | https://conductscience.org/library/papers/8486729 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/950490
GET https://conductscience.org/api/papers/v1/950490/cited_by?page=2